Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population‐based study

Melanoma of unknown primary (MUP) may have a different biology to melanoma of known primary, but clinical trials of novel therapies (e.g., immune checkpoint or BRAF/MEK inhibitors) have not reported the outcomes in this population. We therefore evaluated the overall survival (OS) among patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Verver, D, van der Veldt, AAM, van Akkooi, ACJ, Verhoef, C, Grünhagen, DJ, Louwman, WJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Cancer Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900034/
https://www.ncbi.nlm.nih.gov/pubmed/30801710
http://dx.doi.org/10.1002/ijc.32229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900034/
https://www.ncbi.nlm.nih.gov/pubmed/30801710
http://dx.doi.org/10.1002/ijc.32229

Ejemplares similares